The volatility stems from the company's Q2 2026 financial report, where management attributed the lowered expectations to the evolving ATTR-CM market. Specifically, executives cited the normalization of growth in second-line volume, noting that initial demand had been artificially inflated by patients waiting for new therapy. Investors are now scrutinizing whether these market dynamics were accurately communicated to the public prior to the late-July earnings announcement.

Schall, Brown & Schwartz is currently reviewing claims on behalf of shareholders who incurred losses during the market slide. Firm partners Brian Schall and David Schwartz are inviting affected investors to discuss potential legal recourse, focusing on whether the company issued misleading statements regarding its commercial performance. The investigation aims to determine if Alnylam failed to provide adequate transparency concerning its product launch phase and the sustainability of its growth trajectory.